» Articles » PMID: 37739146

Infections in Haematology Patients Treated with CAR-T Therapies: A Systematic Review and Meta-analysis

Overview
Specialty Hematology
Date 2023 Sep 22
PMID 37739146
Authors
Affiliations
Soon will be listed here.
Abstract

A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group.

Citing Articles

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?.

Kuipers M, Kersten M Lupus Sci Med. 2025; 12(1.

PMID: 39832905 PMC: 11751780. DOI: 10.1136/lupus-2024-001157.


New horizons in our understanding of precursor multiple myeloma and early interception.

Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.

PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.


Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.

Li J, Chen H, Xu C, Hu M, Li J, Chang W Front Immunol. 2024; 15:1422591.

PMID: 39253080 PMC: 11381299. DOI: 10.3389/fimmu.2024.1422591.


Overview of infectious complications among CAR T- cell therapy recipients.

Arya S, Shahid Z Front Oncol. 2024; 14:1398078.

PMID: 39026972 PMC: 11255439. DOI: 10.3389/fonc.2024.1398078.


Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.

Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk J Clin Hematol Int. 2024; 6(2):31-45.

PMID: 38817309 PMC: 11086990. DOI: 10.46989/001c.115932.